TRC120038, a Novel Dual AT<sub><b>1</b></sub>/ET<sub><b>A</b></sub> Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats

<table>Percent incidence of glomeruli in different grades of GSI for ob-ZSF1 rats treated with vehicle, TRC120038, or candesartan. Incidences are significantly different (<svg height="12.5" id="M66" style="vertical-align:-0.546pt" version="1.1" viewbox="0 0 59.3125 12.5" width="59.3125" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,11.762)"><path d="M16 651v25h315q130 0 199.5 -46t69.5 -135q0 -60 -33.5 -104.5t-95.5 -67.5q-29 -11 -71 -16q-30 -2 -138 -4v-192q0 -51 14 -65q13 -13 73 -21v-25h-333v25q33 3 45 9q23 9 31 29t8 63v427q0 59 -16 75q-15 18 -68 23zM262 606v-268q95 2 130 32q36 32 36 114
q0 84 -27 120.5t-89 36.5q-50 0 -50 -35z" id="x1D40F"></path></g><g transform="matrix(.017,-0,0,-.017,15.157,11.762)"><path d="M531 71l-474 214v50l474 215v-56l-416 -184l416 -183v-56zM531 -40h-474v50h474v-50z" id="x2264"></path></g><g transform="matrix(.017,-0,0,-.017,29.861,11.762)"><path d="M476 337q0 -157 -63 -254q-63 -96 -162 -96t-163 96q-64 95 -64 251q0 51 7 99.5t24.5 95.5t43 81.5t65.5 56t89 21.5q75 0 127 -55q96 -97 96 -296zM318 224v225q0 111 -16 161t-53 50t-52 -48.5t-15 -162.5v-225q0 -112 16 -160.5t53 -48.5t52 47.5t15 161.5z" id="x1D7CE"></path></g><g transform="matrix(.017,-0,0,-.017,38.361,11.762)"><path d="M113 -12q-24 0 -39.5 16t-15.5 42q0 24 16 40.5t40 16.5t40 -16.5t16 -40.5q0 -26 -16 -42t-41 -16z" id="x2E"></path></g><g transform="matrix(.017,-0,0,-.017,42.236,11.762)"><path d="M476 337q0 -157 -63 -254q-63 -96 -162 -96t-163 96q-64 95 -64 251q0 51 7 99.5t24.5 95.5t43 81.5t65.5 56t89 21.5q75 0 127 -55q96 -97 96 -296zM318 224v225q0 111 -16 161t-53 50t-52 -48.5t-15 -162.5v-225q0 -112 16 -160.5t53 -48.5t52 47.5t15 161.5z" id="x1D7CE"></path></g><g transform="matrix(.017,-0,0,-.017,50.736,11.762)"><path d="M441 24v-24h-373v24q75 2 96 20q22 19 22 85v378q0 70 -36 70q-26 0 -65 -16l-20 -8v26l251 109h18v-570q0 -57 19 -75q19 -17 88 -19z" id="x1D7CF"></path></g>
</svg>) for TRC120038 versus candesartan and vehicle versus TRC120038 by chi-square test.</table>

International Journal of Hypertension

fig5

Figure 5

Figure 5: TRC120038, a Novel Dual AT<sub><b>1</b></sub>/ET<sub><b>A</b></sub> Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats 

International Journal of Hypertension

TRC120038, a Novel Dual AT1/ETA Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats

Figure 5

TRC120038, a Novel Dual AT₁/ET_A Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats